Symproic® Tablets 0.2mg Approved for the Treatment of Opioid-Induced Constipation in adult patients in Taiwan.

OSAKA, Japan, December 2, 2021 - Shionogi & Co., Ltd. (Head Office: Osaka, Japan; President and CEO: Isao Teshirogi, Ph.D.; hereafter "Shionogi") today announced that Symproic® has been approved in Taiwan for the treatment of opioid-induced constipation (hereafter, “OIC”) in adult patients.


Symproic® is a peripherally-acting mu-opioid receptor antagonist developed by Shionogi .This drug was launched in Japan in June 2017, and in the United States in October 2017, under the product name “Symproic®”. This drug provides a new treatment option for patients with OIC problems in pain management using opioid analgesics. After approval, in Taiwan, Taiwan Shionogi & Co., Ltd., a subsidiary of Shionogi, will launch Symproic® in Taiwan.


Shionogi is committed to “Improve Social Productivity and Extend Healthy Lifespans” as our key focus. We are not only working on R&D of therapeutic agents in the pain field, but also pursuing the realization of total care for a range of diseases, to address a broader range of healthcare needs. We will continue to progress our efforts in the pain field to contribute to improving the quality of life of patients who are suffering from pain  and the side effects caused by pain treatment drugs.


About Taiwan Shionogi & Co., Ltd

Taiwan Shionogi & Co., Ltd was incorporated locally in Taiwan in 1964. It is a wholly owned subsidiary, and also the oldest subsidiary of Shionogi & Co., Ltd, headquartered in Osaka, Japan. Taiwan Shionogi has long history of developing drugs, especially in the field of antibiotics and other anti-infective agents, to preserve the lives and wellbeing of patients. In accordance with their corporate mission, Taiwan Shionogi continuously strives to sustain the lives of patients and improve their quality of life by providing better medicines. In addition to  its main antibiotic products Flumarin® and Finibax®, the antifibrotic Pirespa®, and the anti-influenza drugs Rapiacta® and Xofluza®, Taiwan Shionogi continues to introduce new drugs and to contribute to the medium-and-long term growth of the Shionogi Group.


Forward-Looking Statements

This announcement contains forward-looking statements. These statements are based on expectations in light of the information currently available, assumptions that are subject to risks and uncertainties which could cause actual results to differ materially from these statements. Risks and uncertainties include general domestic and international economic conditions such as general industry and market conditions, and changes of interest rate and currency exchange rate. These risks and uncertainties particularly apply with respect to product-related forward-looking statements. Product risks and uncertainties include, but are not limited to, completion and discontinuation of clinical trials; obtaining regulatory approvals; claims and concerns about product safety and efficacy; technological advances; adverse outcome of important litigation; domestic and foreign healthcare reforms and changes of laws and regulations. Also for existing products, there are manufacturing and marketing risks, which include, but are not limited to, inability to build production capacity to meet demand, lack of availability of raw materials and entry of competitive products. The company disclaims any intention or obligation to update or revise any forward-looking statements whether as a result of new information, future events or otherwise.


For Further Information, Contact:

SHIONOGI Website Inquiry Form : https://www.shionogi.com/global/en/contact.html